Logo image of ENOB

ENOCHIAN BIOSCIENCES INC (ENOB) Stock Fundamental Analysis

NASDAQ:ENOB - Nasdaq - US29350E1047 - Common Stock - Currency: USD

0.7  0 (0%)

After market: 0.7 0 (0%)

Fundamental Rating

1

Overall ENOB gets a fundamental rating of 1 out of 10. We evaluated ENOB against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of ENOB have multiple concerns. ENOB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ENOB had negative earnings in the past year.
In the past year ENOB has reported a negative cash flow from operations.
ENOB had negative earnings in each of the past 5 years.
In the past 5 years ENOB always reported negative operating cash flow.
ENOB Yearly Net Income VS EBIT VS OCF VS FCFENOB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for ENOB are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENOB Yearly ROA, ROE, ROICENOB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

ENOB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENOB Yearly Profit, Operating, Gross MarginsENOB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K -5K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ENOB has more shares outstanding
Compared to 1 year ago, ENOB has a worse debt to assets ratio.
ENOB Yearly Shares OutstandingENOB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
ENOB Yearly Total Debt VS Total AssetsENOB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

ENOB has an Altman-Z score of -2.97. This is a bad value and indicates that ENOB is not financially healthy and even has some risk of bankruptcy.
ENOB has a Altman-Z score of -2.97. This is comparable to the rest of the industry: ENOB outperforms 41.19% of its industry peers.
There is no outstanding debt for ENOB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.97
ROIC/WACCN/A
WACCN/A
ENOB Yearly LT Debt VS Equity VS FCFENOB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M 100M 150M

2.3 Liquidity

ENOB has a Current Ratio of 0.33. This is a bad value and indicates that ENOB is not financially healthy enough and could expect problems in meeting its short term obligations.
ENOB's Current ratio of 0.33 is on the low side compared to the rest of the industry. ENOB is outperformed by 98.14% of its industry peers.
A Quick Ratio of 0.33 indicates that ENOB may have some problems paying its short term obligations.
The Quick ratio of ENOB (0.33) is worse than 97.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
ENOB Yearly Current Assets VS Current LiabilitesENOB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ENOB have decreased strongly by -149.93% in the last year.
EPS 1Y (TTM)-149.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENOB Yearly Revenue VS EstimatesENOB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 0 0 0 0 0
ENOB Yearly EPS VS EstimatesENOB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ENOB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENOB Price Earnings VS Forward Price EarningsENOB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENOB Per share dataENOB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ENOB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENOCHIAN BIOSCIENCES INC

NASDAQ:ENOB (8/4/2023, 8:00:53 PM)

After market: 0.7 0 (0%)

0.7

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)12-13 2022-12-13/amc
Inst Owners25.33%
Inst Owner Change-97.56%
Ins Owners31.21%
Ins Owner Change0%
Market Cap40.80M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS1.13
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z -2.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)69.13%
Cap/Depr(5y)277.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-149.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.36%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.81%
OCF growth 3YN/A
OCF growth 5YN/A